Genprex (GNPX) News Today $2.02 -0.13 (-6.05%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Genprex to Participate in 2024 BIO Europe ConferenceOctober 31, 2024 | prnewswire.comLooking Into Genprex's Recent Short InterestOctober 30, 2024 | benzinga.comGenprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and GlioblastomaOctober 28, 2024 | prnewswire.comGenprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK PositiveOctober 24, 2024 | prnewswire.comGenprex (NASDAQ:GNPX) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.comGenprex advances dose in lung cancer trialOctober 17, 2024 | investing.comGenprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerOctober 15, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 10, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingOctober 7, 2024 | prnewswire.comGenprex, Inc. (GNPX) interactive stock chart – Yahoo FinanceSeptember 25, 2024 | au.finance.yahoo.comGenprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and DiabetesSeptember 23, 2024 | prnewswire.comGenprex Announces Formation of Mesothelioma Clinical Advisory BoardSeptember 19, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsSeptember 9, 2024 | prnewswire.comGenprex Plans To Launch New Subsidiary To Focus Gene Therapy To Treat Type-1, Type-2 DiabetesSeptember 4, 2024 | markets.businessinsider.comGenprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 DiabetesSeptember 4, 2024 | prnewswire.comGenprex to Present and Participate at Upcoming September Investor and Industry ConferencesSeptember 3, 2024 | prnewswire.comGenprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical TrialsAugust 15, 2024 | prnewswire.comGenprex stock slides 14% following Reqorsa study updatesAugust 15, 2024 | msn.comGenprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung CancerAugust 14, 2024 | prnewswire.comGenprex, Inc.: Genprex Granted Patent in Singapore for Reqorsa Gene Therapy with PD-1 Antibodies to Treat CancersAugust 14, 2024 | finanznachrichten.deNasdaq Surges 200 Points; US Producer Prices Increase 0.1% In JulyAugust 13, 2024 | msn.comS&P 500 Gains 1%; Home Depot Earnings Top ViewsAugust 13, 2024 | benzinga.comGenprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat CancersAugust 13, 2024 | prnewswire.comGNPX Stock Earnings: Genprex Reported Results for Q2 2024August 12, 2024 | investorplace.comGenprex to Present at the August Sidoti Microcap ConferenceAugust 8, 2024 | prnewswire.comGenprex Issues Stockholder Letter and Provides 2024 Corporate UpdateJune 27, 2024 | prnewswire.comGenprex to Present at the 2024 BIO International ConventionMay 30, 2024 | prnewswire.comGNPX Stock Earnings: Genprex Beats EPS for Q1 2024May 20, 2024 | msn.comGenprex’s Promising Clinical Trials and Leadership Drive Buy RatingMay 15, 2024 | markets.businessinsider.comGenprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerMay 14, 2024 | prnewswire.comGenprex Appoints Toscano As ChairmanMay 13, 2024 | markets.businessinsider.comGenprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsMay 13, 2024 | prnewswire.comGenprex, Inc.: Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerMay 9, 2024 | finanznachrichten.deGenprex Co-Founder, CEO Rodney Varner Dies of CancerMay 8, 2024 | marketwatch.comGenprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerMay 8, 2024 | prnewswire.comGenprex to Present and Participate at Upcoming May Investor and Industry ConferencesMay 1, 2024 | prnewswire.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 9, 2024 | finance.yahoo.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 9, 2024 | prnewswire.comGenprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock UpApril 3, 2024 | markets.businessinsider.comGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerApril 3, 2024 | prnewswire.comGenprex: Collaborators Report Positive Preclinical Data With NPRL2 Gene TherapyApril 2, 2024 | markets.businessinsider.comGenprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemApril 2, 2024 | prnewswire.comGenprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 22, 2024 | prnewswire.comGenprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8MMarch 21, 2024 | marketwatch.comGenprex Shares Hit 52-Week Low After Direct Offering PricesMarch 20, 2024 | marketwatch.comGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | prnewswire.comGenprex, Inc.: Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | finanznachrichten.deGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | prnewswire.comGenprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 AntibodiesMarch 12, 2024 | markets.businessinsider.comGenprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersMarch 12, 2024 | finance.yahoo.com Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW GNPX Media Mentions By Week GNPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNPX News Sentiment▼-0.250.45▲Average Medical News Sentiment GNPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNPX Articles This Week▼31▲GNPX Articles Average Week Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AYTU News Today ATHA News Today TPST News Today UBX News Today PIRS News Today SPRB News Today APRE News Today CYTH News Today MEIP News Today LSB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNPX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNPX Stock Alerts